Introduction
This analysis examines the current position and future outlook for Lundbeck in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information
Reasons to Purchase
- Assess the company’s successful strategy to preserve sales after the global genericization of Cipramil/Celexa
- Benchmark Lundbeck’s performance against key rivals in the ethical pharmaceutical sector
- Understand why the success of the company’s licensing strategy in obtaining product marketing rights will determine its ability to drive growth
Other selected research from the 'Companies' category:
H. Lundbeck A/S: PharmaVitae Profile
This analysis examines the historical and forecast performance for Lundbeck in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance... Learn More
World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies)
What Will The Pharmaceutical Market Look Like in the Next Five Years? This research undertaking is the result of a detailed analysis of the late stage R&D pipeline of... Learn More
Other selected research from the 'PharmaVitae' category:
Pfizer Inc: PharmaVitae Profile
Introduction This analysis examines the historical and forecast performance for Pfizer in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial... Learn More
Takeda: PharmaVitae Profile 2005
This analysis examines the current position and future outlook for Takeda in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information. Learn More
Other selected research from the 'Companies' category:
Boehringer Ingelheim: PharmaVitae Profile 2005
This analysis examines the current position and future outlook for Boehringer Ingelheim in the pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information. Learn More
Sepracor Inc.: PharmaVitae Profile 2008
Analysis of Sepracor’s corporate strategy, marketed portfolio, pipeline potential and financial position in 2007 and to 2013 Learn More